
The FDA has approved maribavir for the treatment of adults and pediatric patients aged 12 years or older and weighing at least 35 kg with post-transplant cytomegalovirus infection/disease that is refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet.



























